Morphic Holding, Inc. (MORF)
| Market Cap | 896.65M |
| Revenue (ttm) | 18.91M |
| Net Income (ttm) | -105.74M |
| Shares Out | 38.27M |
| EPS (ttm) | -2.67 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 102,568 |
| Open | 23.72 |
| Previous Close | 24.53 |
| Day's Range | 23.22 - 24.39 |
| 52-Week Range | 21.20 - 68.75 |
| Beta | 1.29 |
| Analysts | Buy |
| Price Target | 71.40 (+204.7%) |
| Earnings Date | May 5, 2022 |
About MORF
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibro...
Financial Performance
In 2021, MORF's revenue was $19.79 million, a decrease of -55.96% compared to the previous year's $44.95 million. Losses were -$95.54 million, 112.3% more than in 2020.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for MORF stock is "Buy." The 12-month stock price forecast is 71.4, which is an increase of 204.74% from the latest price.
News
Morphic Appoints Joanne Gibbons as Senior Vice President of Regulatory Affairs
Experienced Regulatory Leader with Record of Global and Regulatory Success Across Multiple Therapeutic Areas Experienced Regulatory Leader with Record of Global and Regulatory Success Across Multiple Th...
Morphic Holding, Inc. (MORF) Reports Q1 Loss, Misses Revenue Estimates
Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of -19.72% and 52.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2022
Initiated EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis
Strength Seen in Morphic Holding, Inc. (MORF): Can Its 7% Jump Turn into More Strength?
Morphic Holding, Inc. (MORF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price ...
Morphic to Participate in BMO Inflammation and Immunology Spotlight Series Panel
WALTHAM, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chr...
Morphic Therapeutic Announces Initiation of EMERALD-1 Phase 2a Clinical Trial of MORF-057 in Patients with Ulcerative...
MORF-057, an oral α4β7 integrin inhibitor candidate, holds potential for treating inflammatory bowel diseases
Morphic Announces Participation In Cowen 42nd Annual Healthcare Conference
WALTHAM, Mass., March 04, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chr...
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2021
Presented positive Phase 1 data for MORF-057
Morphic Holding, Inc. (MORF) Upgraded to Buy: What Does It Mean for the Stock?
Morphic Holding, Inc. (MORF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Morphic Therapeutic to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic ...
Morphic Presents Preclinical Data from αvβ8 Integrin Program at the SITC Annual Meeting
αvβ8 inhibition demonstrates efficacy in a cancer model refractory to radiation and checkpoint inhibition
Morphic Holding, Inc. (MORF) Reports Q3 Loss, Lags Revenue Estimates
Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of 9.21% and -47.93%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Morphic Announces Corporate Highlights and Third Quarter 2021 Financial Results
MORF-057 phase 1 safety, receptor occupancy, PK and mechanistic measures exceeded objectives; phase 2 program in ulcerative colitis expected to begin 1Q22
Analysts Estimate Morphic Holding, Inc. (MORF) to Report a Decline in Earnings: What to Look Out for
Morphic Holding, Inc. (MORF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Morphic to Participate in Jefferies IBD Therapeutics Summit
WALTHAM, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic ...
New Strong Sell Stocks for September 16th
CLMT, FANH, and MORF have been added to the Zacks Rank #5 (Strong Sell) List on September 16, 2021.
Morphic Therapeutic Announces Appointment of Nisha Nanda, Ph.D., to Board of Directors
WALTHAM, Mass., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chro...
Morphic Holding, Inc. (MORF) Reports Q2 Loss, Misses Revenue Estimates
Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of -40.00% and -35.87%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Morphic Announces Corporate Highlights and Second Quarter 2021 Financial Results
MORF-057 phase 1 safety, receptor occupancy, PK and mechanistic measures exceeded objectives; phase 2 program expected to begin 1Q22
Earnings Preview: Morphic Holding, Inc. (MORF) Q2 Earnings Expected to Decline
Morphic Holding, Inc. (MORF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Morphic Therapeutic Shares New Positive MORF-057 Data From IBD Study
Morphic Therapeutic (NASDAQ: MORF) has announced additional data from its Phase 1 trial evaluating MORF-057 for inflammatory bowel disease (IBD). The data were shared at the Congress of European Crohn'...
Morphic Reports New Data from Positive Phase 1 Study of MORF-057, Oral Integrin Inhibitor Candidate for IBD
MORF-057 well tolerated across all phase 1 cohorts
Morphic Therapeutic to Host Analyst and Investor Call on July 9, 2021
Call to discuss positive results from Phase 1 trial of MORF-057 to be presented at ECCO 2021 Virtual Congress Call to discuss positive results from Phase 1 trial of MORF-057 to be presented at ECCO 2021...
Strength Seen in Morphic Holding, Inc. (MORF): Can Its 6% Jump Turn into More Strength?
Morphic Holding, Inc. (MORF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near t...
Morphic Therapeutic to Present Positive Phase 1 Data for MORF-057 at ECCO'21 Virtual Congress
Presentation will include summary safety, pharmacokinetic and pharmacodynamic data from single ascending dose (SAD), food effect and multiple ascending dose (MAD) studies